GENELUX CORP (GNLX)
US36870H1032 - Common Stock
GNLX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. GNLX has a great financial health rating, but its profitability evaluates not so good. GNLX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year GNLX has reported negative net income.
GNLX had a negative operating cash flow in the past year.
GNLX had negative earnings in each of the past 5 years.
GNLX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
GNLX has a Return On Assets of -58.74%. This is comparable to the rest of the industry: GNLX outperforms 41.26% of its industry peers.
With a Return On Equity value of -70.45%, GNLX perfoms like the industry average, outperforming 56.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.74% | ||
| ROE | -70.45% | ||
| ROIC | N/A |
ROA(3y)-132.38%
ROA(5y)-169.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GNLX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GNLX has been increased compared to 1 year ago.
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
GNLX has an Altman-Z score of -1.53. This is a bad value and indicates that GNLX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.53, GNLX is in line with its industry, outperforming 54.59% of the companies in the same industry.
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.53 |
ROIC/WACCN/A
WACC9.92%
2.3 Liquidity
A Current Ratio of 6.01 indicates that GNLX has no problem at all paying its short term obligations.
GNLX has a Current ratio of 6.01. This is in the better half of the industry: GNLX outperforms 60.54% of its industry peers.
GNLX has a Quick Ratio of 6.01. This indicates that GNLX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.01, GNLX is in the better half of the industry, outperforming 60.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.01 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
The earnings per share for GNLX have decreased strongly by -451.58% in the last year.
GNLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -98.46%.
EPS 1Y (TTM)-451.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
Revenue 1Y (TTM)-98.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, GNLX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.73% on average per year.
The Revenue is expected to grow by 273.32% on average over the next years. This is a very strong growth
EPS Next Y25.4%
EPS Next 2Y-0.05%
EPS Next 3Y-2.74%
EPS Next 5Y13.73%
Revenue Next Year-97.75%
Revenue Next 2Y-41.42%
Revenue Next 3Y223.63%
Revenue Next 5Y273.33%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GNLX. In the last year negative earnings were reported.
Also next year GNLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as GNLX's earnings are expected to decrease with -2.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.05%
EPS Next 3Y-2.74%
5. Dividend
5.1 Amount
GNLX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENELUX CORP
NASDAQ:GNLX (1/6/2025, 8:00:01 PM)
After market: 2.66 +0.12 (+4.72%)2.54
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners20.54%
Inst Owner Change0%
Ins Owners17.85%
Ins Owner Change32.5%
Market Cap87.73M
Analysts83.64
Price Target18.77 (638.98%)
Short Float %5.5%
Short Ratio10.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.25%
Min EPS beat(2)-20.98%
Max EPS beat(2)-13.52%
EPS beat(4)0
Avg EPS beat(4)-18.62%
Min EPS beat(4)-29%
Max EPS beat(4)-10.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.82%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)-1.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10966.45 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.33 | ||
| P/tB | 2.33 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.95
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0
BVpS1.09
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.74% | ||
| ROE | -70.45% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-132.38%
ROA(5y)-169.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 220.23% | ||
| Cap/Sales | 9662.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.01 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | -1.53 |
F-Score3
WACC9.92%
ROIC/WACCN/A
Cap/Depr(3y)71.5%
Cap/Depr(5y)136.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-451.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
EPS Next Y25.4%
EPS Next 2Y-0.05%
EPS Next 3Y-2.74%
EPS Next 5Y13.73%
Revenue 1Y (TTM)-98.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-97.75%
Revenue Next 2Y-41.42%
Revenue Next 3Y223.63%
Revenue Next 5Y273.33%
EBIT growth 1Y-217.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2263.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2230.76%
OCF growth 3YN/A
OCF growth 5YN/A